NCT05816733View on ClinicalTrials.gov

Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure

PHASE4RecruitingINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

June 7, 2024

Study Completion Date

August 7, 2024

Conditions
Atrial Fibrillation RecurrenceCox Maze IVAtrial FibrillationPatients With or Without Heart Failure and Diabetes
Interventions
DRUG

Dapagliflozin

Patients randomized in this arm will receive dapagliflozin at a target dose of 10mg once daily and routine treatment.

DRUG

Placebo

Patients randomized in this arm will receive placebo at a target dose of 10mg once daily and routine treatment.

Trial Locations (1)

100029

RECRUITING

Cardiac Surgery Center No. 7, Beijing

All Listed Sponsors
lead

Kun Hua

OTHER